Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2025)
Candel Therapeutics (CADL) posted Non-Current Deffered Revenue of $89000.0 for Q4 2025, down 17.59% sequentially from $108000.0 in Q3 2023.
Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $89000.0 in Q4 2025.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $89000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $89000.0 (changed N/A YoY) and the FY2025 annual result came in at $89000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue fell to $89000.0 in Q4 2025 per CADL's latest filing, from $108000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $894000.0 in Q4 2021 and troughed at $63000.0 in Q2 2021.
- A 4-year average of $263000.0 and a median of $126000.0 in 2023 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2021 and 2022: Non-Current Deffered Revenue surged 41.46% in 2021, then sank 83.89% in 2022.
- Over 4 years, Non-Current Deffered Revenue stood at $894000.0 in 2021, then tumbled by 83.89% to $144000.0 in 2022, then retreated by 25.0% to $108000.0 in 2023, then decreased by 17.59% to $89000.0 in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $89000.0, $108000.0, and $120000.0 for Q4 2025, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 89,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 89,000.00 |
| Sep 30, 2023 | 108,000.00 |
| Jun 30, 2023 | 120,000.00 |
| Mar 31, 2023 | 132,000.00 |
| Dec 31, 2022 | 144,000.00 |
| Dec 31, 2021 | 894,000.00 |
| Sep 30, 2021 | 554,000.00 |
| Jun 30, 2021 | 63,000.00 |
| Dec 31, 2020 | 632,000.00 |